Dataset Information

Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia.

ABSTRACT:

Objectives

Early recognition of dementia would allow patients and their families to receive care earlier in the disease process, potentially improving care management and patient outcomes, yet nearly half of patients with dementia are undiagnosed. Our aim was to develop and validate an electronic health record (EHR)-based tool to help detect patients with unrecognized dementia (EHR Risk of Alzheimer's and Dementia Assessment Rule [eRADAR]).

Design

Retrospective cohort study.

Setting

Kaiser Permanente Washington (KPWA), an integrated healthcare delivery system.

Participants

A total of 16 665 visits among 4330 participants in the Adult Changes in Thought (ACT) study, who undergo a comprehensive process to detect and diagnose dementia every 2?years and have linked KPWA EHR data, divided into development (70%) and validation (30%) samples.

Measurements

EHR predictors included demographics, medical diagnoses, vital signs, healthcare utilization, and medications within the previous 2?years. Unrecognized dementia was defined as detection in ACT before documentation in the KPWA EHR (ie, lack of dementia or memory loss diagnosis codes or dementia medication fills).

Results

Overall, 1015 ACT visits resulted in a diagnosis of incident dementia, of which 498 (49%) were unrecognized in the KPWA EHR. The final 31-predictor model included markers of dementia-related symptoms (eg, psychosis diagnoses, antidepressant fills), healthcare utilization pattern (eg, emergency department visits), and dementia risk factors (eg, cerebrovascular disease, diabetes). Discrimination was good in the development (C statistic = .78; 95% confidence interval [CI] = .76-.81) and validation (C statistic = .81; 95% CI = .78-.84) samples, and calibration was good based on plots of predicted vs observed risk. If patients with scores in the top 5% were flagged for additional evaluation, we estimate that 1 in 6 would have dementia.

Conclusion

The eRADAR tool uses existing EHR data to detect patients with good accuracy who may have unrecognized dementia. J Am Geriatr Soc 68:103-111, 2019.

SUBMITTER: Barnes DE

PROVIDER: S-EPMC7094818 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia.

Barnes Deborah E DE Zhou Jing J Walker Rod L RL Larson Eric B EB Lee Sei J SJ Boscardin W John WJ Marcum Zachary A ZA Dublin Sascha S

Journal of the American Geriatrics Society 20191014 1

<h4>Objectives</h4>Early recognition of dementia would allow patients and their families to receive care earlier in the disease process, potentially improving care management and patient outcomes, yet nearly half of patients with dementia are undiagnosed. Our aim was to develop and validate an electronic health record (EHR)-based tool to help detect patients with unrecognized dementia (EHR Risk of Alzheimer's and Dementia Assessment Rule [eRADAR]).<h4>Design</h4>Retrospective cohort study.<h4>Se ...[more]

PMID: 31612463

Similar Datasets

Project description:Objectives:Brief cognitive tests are recommended in clinical services outside of specialized memory clinics as case-finding tools to reduce the diagnostic gap of dementia. Although the Montreal Cognitive Assessment (MoCA) is among the most widely used brief tests in specialized memory clinics, its length precludes routine use in nonspecialty clinics. This study investigated whether a small subset of MoCA would suffice to match the performance of the full MoCA in detecting dementia and, hence, be useful in nonspecialty clinics.Design:Cross-sectional test research.Setting:Alzheimer's Disease Centers across the United States.Participants:Participants age ?65 years (n = 8773).Measures:Participants completed MoCA and were evaluated for dementia. The study sample was split into 2: the derivation sample (n = 4386) was used to develop a short variant of MoCA that best distinguish dementia (using the best-subset-approach with 10-fold cross-validation), while the validation sample (n = 4387) verified its actual performance using area under the receiver operating characteristic-curve (AUC).Results:A 4-item cognitive test was identified, comprising Clock-drawing, Tap-at-letter-A, Orientation, and Delayed-recall. It demonstrated excellent performance in distinguishing dementia from nondementia (AUC 94.2%) and was comparable to that of MoCA (AUC 93.8%), even across education subgroups. It explained 85.9% of the variability in MoCA and had scores that could be mapped to MoCA with reasonable precision. At the optimal cut-off score of <10, it demonstrated 87.9% sensitivity and 87.6% specificity in detecting dementia.Conclusions and implications:Using rigorous methods, this study developed a brief cognitive test that is free of charge, takes <5 minutes to complete, covers the key cognitive domains, and has standardized instructions to allow its administration even by nonphysicians. This brief test is well suited as a case-finding tool in nonspecialty clinics (such as in primary care and geriatric clinics) and may improve care-integration with specialized memory clinics that utilize MoCA.

Project description:ImportanceA deep learning system (DLS) that could automatically detect glaucomatous optic neuropathy (GON) with high sensitivity and specificity could expedite screening for GON.ObjectiveTo establish a DLS for detection of GON using retinal fundus images and glaucoma diagnosis with convoluted neural networks (GD-CNN) that has the ability to be generalized across populations.Design, setting, and participantsIn this cross-sectional study, a DLS for the classification of GON was developed for automated classification of GON using retinal fundus images obtained from the Chinese Glaucoma Study Alliance, the Handan Eye Study, and online databases. The researchers selected 241 032 images were selected as the training data set. The images were entered into the databases on June 9, 2009, obtained on July 11, 2018, and analyses were performed on December 15, 2018. The generalization of the DLS was tested in several validation data sets, which allowed assessment of the DLS in a clinical setting without exclusions, testing against variable image quality based on fundus photographs obtained from websites, evaluation in a population-based study that reflects a natural distribution of patients with glaucoma within the cohort and an additive data set that has a diverse ethnic distribution. An online learning system was established to transfer the trained and validated DLS to generalize the results with fundus images from new sources. To better understand the DLS decision-making process, a prediction visualization test was performed that identified regions of the fundus images utilized by the DLS for diagnosis.ExposuresUse of a deep learning system.Main outcomes and measuresArea under the receiver operating characteristics curve (AUC), sensitivity and specificity for DLS with reference to professional graders.ResultsFrom a total of 274 413 fundus images initially obtained from CGSA, 269 601 images passed initial image quality review and were graded for GON. A total of 241 032 images (definite GON 29 865 [12.4%], probable GON 11 046 [4.6%], unlikely GON 200 121 [83%]) from 68 013 patients were selected using random sampling to train the GD-CNN model. Validation and evaluation of the GD-CNN model was assessed using the remaining 28 569 images from CGSA. The AUC of the GD-CNN model in primary local validation data sets was 0.996 (95% CI, 0.995-0.998), with sensitivity of 96.2% and specificity of 97.7%. The most common reason for both false-negative and false-positive grading by GD-CNN (51 of 119 [46.3%] and 191 of 588 [32.3%]) and manual grading (50 of 113 [44.2%] and 183 of 538 [34.0%]) was pathologic or high myopia.Conclusions and relevanceApplication of GD-CNN to fundus images from different settings and varying image quality demonstrated a high sensitivity, specificity, and generalizability for detecting GON. These findings suggest that automated DLS could enhance current screening programs in a cost-effective and time-efficient manner.

Dataset Information

Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia.

Objectives

Design

Setting

Participants

Measurements

Results

Conclusion

Publications

Development and Validation of eRADAR: A Tool Using EHR Data to Detect Unrecognized Dementia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets